Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) shares were up 8.1% during trading on Monday . The company traded as high as $18.24 and last traded at $18.19. Approximately 53,546 shares were traded during trading, a decline of 70% from the average daily volume of 178,568 shares. The stock had previously closed at $16.82.
Analyst Ratings Changes
Several analysts have issued reports on the stock. Wedbush reaffirmed an "outperform" rating and issued a $35.00 price target on shares of Zenas BioPharma in a report on Thursday, May 15th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Zenas BioPharma in a report on Friday, May 16th. Finally, Wall Street Zen cut Zenas BioPharma from a "hold" rating to a "sell" rating in a research note on Saturday.
Check Out Our Latest Analysis on ZBIO
Zenas BioPharma Stock Performance
The company has a market capitalization of $714.61 million and a price-to-earnings ratio of -4.78. The firm has a 50-day moving average price of $12.74.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($1.25) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.23).
Institutional Trading of Zenas BioPharma
A number of hedge funds and other institutional investors have recently modified their holdings of the company. New York State Common Retirement Fund acquired a new position in shares of Zenas BioPharma in the 1st quarter worth $49,000. PNC Financial Services Group Inc. lifted its stake in Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock valued at $89,000 after buying an additional 2,679 shares in the last quarter. Sei Investments Co. purchased a new position in shares of Zenas BioPharma in the second quarter worth approximately $118,000. Intech Investment Management LLC raised its holdings in shares of Zenas BioPharma by 13.9% during the second quarter. Intech Investment Management LLC now owns 13,206 shares of the company's stock valued at $128,000 after acquiring an additional 1,607 shares during the period. Finally, Bank of America Corp DE lifted its position in shares of Zenas BioPharma by 32.3% in the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company's stock valued at $136,000 after acquiring an additional 3,412 shares in the last quarter.
Zenas BioPharma Company Profile
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zenas BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas BioPharma wasn't on the list.
While Zenas BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access